Therapeutics(LENZ),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

LENZ Therapeutics

Market Closed 05-31 16:00:00 EDT

15.29

-0.22

-1.42%

盘后15.29

+0.000.00%

16:08 EDT

High15.79	Low15.13	Vol123.98K
Open15.49	D1 Closing15.51	Amplitude4.26%
Mkt Cap390.42M	Tradable Cap147.03M	Total Shares25.53M
T/O1.91M	T/O Rate1.29%	Tradable Shares9.62M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

{"stockData":{"symbol":"LENZ","market":"US","secType":"STK","nameCN":"Therapeutics","latestPrice":15.29,"timestamp":1717185600000,"preClose":15.51,"halted":0,"volume":123978,"hourTrading":{"tag":"盘后","latestPrice":15.29,"preClose":15.29,"latestTime":"16:08 EDT","volume":250,"amount":3822.555,"timestamp":1717186125949},"delay":0,"floatShares":9616210,"shares":25534458,"eps":-7.123353,"marketStatus":"Market Closed","change":-0.22,"latestTime":"05-31 16:00:00 EDT","open":15.49,"high":15.79,"low":15.13,"amount":1909586.736,"amplitude":0.042553,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-7.123353,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Market Trading","tradingStatus":1,"beginTime":1717401600000},"marketStatusCode":7,"adr":0,"listingDate":1624593600000,"exchange":"NASDAQ","adjPreClose":15.51,"postHourTrading":{"tag":"盘后","latestPrice":15.29,"preClose":15.29,"latestTime":"16:08 EDT","volume":250,"amount":3822.555,"timestamp":1717186125949},"volumeRatio":0.5120886768132812},"requestUrl":"/m/hq/s/LENZ/tweets","defaultTab":"tweets","newsList":[{"id":"2440411327","title":"PYC Therapeutics Insider Buyers Pleased With AU$14m Return On Investment","url":"https://stock-news.laohu8.com/highlight/detail?id=2440411327","media":"Simply Wall St.","top":-1,"share":"https://ttm.financial/m/news/2440411327?lang=en_us&edition=fundamental","pubTime":"2024-06-02 06:28","pubTimestamp":1717280934,"startTime":"0","endTime":"0","summary":"Insiders who bought PYC Therapeutics Limited ( ASX:PYC ) in the last 12 months may probably not pay attention to the...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-pyc/pyc-therapeutics-shares/news/pyc-therapeutics-insider-buyers-pleased-with-au14m-return-on","is_publish_highlight":false,"gpt_icon":0},{"id":"2440131855","title":"BRIEF-Werewolf Therapeutics To Present Data From Ongoing Phase 1/1B Clinical Trial Of Wtx-124 As Monotherapy And In Combination With Pembrolizumab In Solid Tumors","url":"https://stock-news.laohu8.com/highlight/detail?id=2440131855","media":"Reuters","top":-1,"share":"https://ttm.financial/m/news/2440131855?lang=en_us&edition=fundamental","pubTime":"2024-06-01 21:04","pubTimestamp":1717247077,"startTime":"0","endTime":"0","summary":"Werewolf Therapeutics Inc   :   * WEREWOLF THERAPEUTICS TO PRESENT DATA FROM ONGOING PHASE 1/1B CLINICAL TRIAL OF WTX-124 AS MONOTHERAPY AND IN COMBINATION WITH PEMBROLIZUMAB IN SOLID TUMORS   * WEREWOLF THERAPEUTICS: WTX-124 SHOWN TO BE CLINICALLY ACTIVE AND GENERALLY WELL-TOLERATED IN PATIENTSSource text for Eikon:    Further company coverage:","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2440139214","title":"Werewolf Therapeutics to Present Data from Ongoing Phase 1/1b Clinical Trial of WTX-124 as Monotherapy and in Combination with Pembrolizumab in Solid Tumors","url":"https://stock-news.laohu8.com/highlight/detail?id=2440139214","media":"GlobeNewswire","top":-1,"share":"https://ttm.financial/m/news/2440139214?lang=en_us&edition=fundamental","pubTime":"2024-06-01 21:00","pubTimestamp":1717246800,"startTime":"0","endTime":"0","summary":"- WTX-124 was shown to be clinically active and generally well-tolerated in patients who were relapsed/refractory to immune checkpoint inhibitor therapy - - Encouraging single agent clinical activity ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2024/06/01/2891818/0/en/Werewolf-Therapeutics-to-Present-Data-from-Ongoing-Phase-1-1b-Clinical-Trial-of-WTX-124-as-Monotherapy-and-in-Combination-with-Pembrolizumab-in-Solid-Tumors.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2440508135","title":"Kymera Therapeutics Presents New Clinical Data from Ongoing Phase 1 Trial of MDM2 Degrader KT-253 at ASCO Annual Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2440508135","media":"GlobeNewswire","top":-1,"share":"https://ttm.financial/m/news/2440508135?lang=en_us&edition=fundamental","pubTime":"2024-06-01 20:00","pubTimestamp":1717243200,"startTime":"0","endTime":"0","summary":"KT-253 demonstrates initial clinical proof of concept in patients with tumor types shown to be sensitive in preclinical models, including responses in MCC and AML Evidence of target engagement and pot","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2024/06/01/2891812/0/en/Kymera-Therapeutics-Presents-New-Clinical-Data-from-Ongoing-Phase-1-Trial-of-MDM2-Degrader-KT-253-at-ASCO-Annual-Meeting.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2440215659","title":"Contineum Therapeutics Sets Executive Severance Plan","url":"https://stock-news.laohu8.com/highlight/detail?id=2440215659","media":"TIPRANKS","top":-1,"share":"https://ttm.financial/m/news/2440215659?lang=en_us&edition=fundamental","pubTime":"2024-06-01 06:00","pubTimestamp":1717192852,"startTime":"0","endTime":"0","summary":"Contineum Therapeutics, Inc. Class A (CTNM) has shared an announcement. Contineum Therapeutics, Inc. has implemented an Executive Severance Plan to...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/contineum-therapeutics-sets-executive-severance-plan?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/contineum-therapeutics-sets-executive-severance-plan?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"gpt_icon":0},{"id":"2440255109","title":"BRIEF-Aligos Therapeutics Inc -  On May 29, Received Notice Of Delisting Or Failure To Satisfy A Continued Listing Rule Or Standard From Nasdaq","url":"https://stock-news.laohu8.com/highlight/detail?id=2440255109","media":"Reuters","top":-1,"share":"https://ttm.financial/m/news/2440255109?lang=en_us&edition=fundamental","pubTime":"2024-06-01 05:04","pubTimestamp":1717189496,"startTime":"0","endTime":"0","summary":"Aligos Therapeutics Inc   :   * ALIGOS THERAPEUTICS INC -  ON MAY 29, RECEIVED NOTICE OF DELISTING OR FAILURE TO SATISFY A CONTINUED LISTING RULE OR STANDARD FROM NASDAQSource text for Eikon:    Further company coverage:","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2440592360","title":"BRIEF-Allogene Therapeutics Inc On May 24, Co, Overland Pharmaceuticals, Allogene Overland Biopharm Entered Into A Share Exchange Agreement","url":"https://stock-news.laohu8.com/highlight/detail?id=2440592360","media":"Reuters","top":-1,"share":"https://ttm.financial/m/news/2440592360?lang=en_us&edition=fundamental","pubTime":"2024-06-01 04:49","pubTimestamp":1717188586,"startTime":"0","endTime":"0","summary":"Allogene Therapeutics Inc   :   * ALLOGENE THERAPEUTICS INC: ON MAY 24, CO, OVERLAND PHARMACEUTICALS, ALLOGENE OVERLAND BIOPHARM ENTERED INTO A SHARE EXCHANGE AGREEMENT   * ALLOGENE THERAPEUTICS: UNDER SHARE EXCHANGE AGREEMENT, JV COMPANY ACQUIRED FROM OVERLAND 100% EQUITY INTEREST IN OVERLAND PHARMACEUTICALS  INCSource text for Eikon:    Further company coverage:","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2440949795","title":"Adaptimmune Therapeutics: A Hold Rating Amid Strategic Shifts and Delayed Revenue Prospects","url":"https://stock-news.laohu8.com/highlight/detail?id=2440949795","media":"TIPRANKS","top":-1,"share":"https://ttm.financial/m/news/2440949795?lang=en_us&edition=fundamental","pubTime":"2024-06-01 02:46","pubTimestamp":1717181196,"startTime":"0","endTime":"0","summary":"In a report released today, Yanan Zhu from Wells Fargo maintained a Hold rating on Adaptimmune Therapeutics (ADAP – Research Report), with a price ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/adaptimmune-therapeutics-a-hold-rating-amid-strategic-shifts-and-delayed-revenue-prospects?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/adaptimmune-therapeutics-a-hold-rating-amid-strategic-shifts-and-delayed-revenue-prospects?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"gpt_icon":0},{"id":"2440232912","title":"Summit Therapeutics' Lung Cancer Therapy Ivonescimab Shows Improved Progression-Free Survival Versus Merck's Multi-Billion Keytruda In China Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2440232912","media":"Benzinga","top":-1,"share":"https://ttm.financial/m/news/2440232912?lang=en_us&edition=fundamental","pubTime":"2024-06-01 00:21","pubTimestamp":1717172475,"startTime":"0","endTime":"0","summary":"On Friday, Summit Therapeutics Inc  shares are trading lower after the company’s stock closed 272.1% higher at $10.92 on Thursday.Thursday, Summit Therapeutics Inc  announced that Phase 3 HARMONi-2, or AK112-303, met its primary endpoint of progression-free survival .HARMONi-2 evaluated monotherapy ivonescimab against monotherapy pembrolizumab in patients with locally advanced or metastatic non-small cell lung cancer  whose tumors have positive PD-L1 expression .The HARMONi-2 is a single-region, multi-center, double-blinded Phase 3 study conducted in China sponsored by Akeso Inc. with data generated and analyzed by Akeso.At a prespecified interim analysis conducted by an independent Data Monitoring Committee, ivonescimab demonstrated a statistically significant and clinically meaningful improvement in PFS by the blinded independent central radiology review committee  compared to Merck & Co Inc’s  Keytruda .The progression-free survival  benefit was demonstrated across clinical subgroup","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/pGxH7MDmLNYjxpFpDQKMXA--~B/aD01NTM7dz05ODM7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/Benzinga/b4c8da6d67603ee3df2d1119f05d3c58","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/pGxH7MDmLNYjxpFpDQKMXA--~B/aD01NTM7dz05ODM7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/Benzinga/b4c8da6d67603ee3df2d1119f05d3c58"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/summit-therapeutics-lung-cancer-therapy-162115009.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2439996911","title":"Arecor Therapeutics Sets Date for 2024 AGM","url":"https://stock-news.laohu8.com/highlight/detail?id=2439996911","media":"TIPRANKS","top":-1,"share":"https://ttm.financial/m/news/2439996911?lang=en_us&edition=fundamental","pubTime":"2024-05-31 23:29","pubTimestamp":1717169360,"startTime":"0","endTime":"0","summary":"Arecor Therapeutics PLC (GB:AREC) has released an update. Arecor Therapeutics PLC, a biopharmaceutical firm focused on enhancing therapies for heal...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/arecor-therapeutics-sets-date-for-2024-agm?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/arecor-therapeutics-sets-date-for-2024-agm?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"gpt_icon":0},{"id":"2439919679","title":"Buy Rating Affirmed for Iterum Therapeutics Amid Positive Sulopenem Prospects and Financial Stability","url":"https://stock-news.laohu8.com/highlight/detail?id=2439919679","media":"TIPRANKS","top":-1,"share":"https://ttm.financial/m/news/2439919679?lang=en_us&edition=fundamental","pubTime":"2024-05-31 23:25","pubTimestamp":1717169117,"startTime":"0","endTime":"0","summary":"Iterum Therapeutics (ITRM – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Ed Arce from H.C...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/buy-rating-affirmed-for-iterum-therapeutics-amid-positive-sulopenem-prospects-and-financial-stability?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/buy-rating-affirmed-for-iterum-therapeutics-amid-positive-sulopenem-prospects-and-financial-stability?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"gpt_icon":0},{"id":"2439913752","title":"Larimar Therapeutics Shares Rise 15% Nomlabofusp Selected for FDA Program","url":"https://stock-news.laohu8.com/highlight/detail?id=2439913752","media":"Dow Jones","top":-1,"share":"https://ttm.financial/m/news/2439913752?lang=en_us&edition=fundamental","pubTime":"2024-05-31 22:43","pubTimestamp":1717166580,"startTime":"0","endTime":"0","summary":"Larimar Therapeutics shares were up 15% at $8.17 after the company said the Food and Drug Administration has selected nomlabofusp to participate in the Support for Clinical Trials Advancing Rare Disease Therapeutics pilot program.Nomlabofusp is Larimar's novel protein replacement therapy designed to address the root cause of Friedreich's ataxia by delivering frataxin to mitochondria.The FDA's START selection was based on demonstrated development program readiness, and provides a path to potential Biologics License Application submission.The START pilot program was launched by the FDA in September 2023 to further accelerate the pace of development, with an initial selection of up to six novel drugs, three by the Center for Drug Evaluation and Research, and three by the Center for Biologics Evaluation and Research, intended to treat a rare disease or other serious condition with high unmet medical need through an enhanced mechanism for communication with the FDA.Nomlabofusp is currently ","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"gpt_icon":0},{"id":"2439180299","title":"Astria Therapeutics’ STAR-0215: A Strong Buy on Potential Market Leadership in HAE Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=2439180299","media":"TIPRANKS","top":-1,"share":"https://ttm.financial/m/news/2439180299?lang=en_us&edition=fundamental","pubTime":"2024-05-31 22:25","pubTimestamp":1717165517,"startTime":"0","endTime":"0","summary":"LifeSci Capital analyst Sam Slutsky maintained a Buy rating on Astria Therapeutics (ATXS – Research Report) today and set a price target of $25.00....","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/astria-therapeutics-star-0215-a-strong-buy-on-potential-market-leadership-in-hae-treatment?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/astria-therapeutics-star-0215-a-strong-buy-on-potential-market-leadership-in-hae-treatment?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"gpt_icon":0},{"id":"2439992431","title":"Summit Therapeutics Stock: Plunging Despite A Win?","url":"https://stock-news.laohu8.com/highlight/detail?id=2439992431","media":"seekingalpha","top":-1,"share":"https://ttm.financial/m/news/2439992431?lang=en_us&edition=fundamental","pubTime":"2024-05-31 21:27","pubTimestamp":1717162050,"startTime":"0","endTime":"0","summary":"Summit Therapeutics has achieved massive market success in 2024, with a market capitalization of over $7 billion.Summit's main pipeline candidate is ivonescimab, a bispecific antibody targeting both P","market":"sg","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/679379743/image_679379743.jpg","type":0,"news_type":0,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/679379743/image_679379743.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/article/4696722-summit-therapeutics-stock-plunging-despite-win","is_publish_highlight":false,"gpt_icon":0},{"id":"2439899978","title":"Iterum Therapeutics Strategizes for NASDAQ Compliance and FDA Review","url":"https://stock-news.laohu8.com/highlight/detail?id=2439899978","media":"TIPRANKS","top":-1,"share":"https://ttm.financial/m/news/2439899978?lang=en_us&edition=fundamental","pubTime":"2024-05-31 20:58","pubTimestamp":1717160337,"startTime":"0","endTime":"0","summary":"Iterum Therapeutics (ITRM) has shared an update. Iterum Therapeutics International Limited has contracted its outgoing Chief Medical Officer, Dr. S...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/iterum-therapeutics-strategizes-for-nasdaq-compliance-and-fda-review?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/iterum-therapeutics-strategizes-for-nasdaq-compliance-and-fda-review?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"gpt_icon":0},{"id":"2439136995","title":"Viridian Therapeutics Announces Participation in Upcoming June Investor Conferences","url":"https://stock-news.laohu8.com/highlight/detail?id=2439136995","media":"Business Wire","top":-1,"share":"https://ttm.financial/m/news/2439136995?lang=en_us&edition=fundamental","pubTime":"2024-05-31 20:00","pubTimestamp":1717156800,"startTime":"0","endTime":"0","summary":"WALTHAM, Mass., May 31, 2024----Viridian Therapeutics, Inc. , a biopharmaceutical company focused on discovering and developing potential best-in-class medicines for serious and rare diseases, today announced that senior management will participate in the following upcoming investor conferences in June:. Jefferies Global Healthcare Conference : Presentation on Wednesday, June 5, 2024, at 5:00 p.m. ET.Goldman Sachs 45th Annual Global Healthcare Conference : Presentation on Tuesday June 11, 2024, at 8:40 a.m. ET.Viridian is a biopharmaceutical company focused on engineering and developing potential best-in-class medicines for patients with serious and rare diseases. Viridian’s expertise in antibody discovery and protein engineering enables the development of differentiated therapeutic candidates for previously validated drug targets in commercially established disease areas.Viridian is advancing multiple candidates in the clinic for the treatment of patients with thyroid eye disease . Th","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/d3NndmnysNzcYyxf6O0CoA--~B/aD02MDA7dz0yNDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/business-wire.com/c4e480fc068297aa2a38c658567ba598","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/d3NndmnysNzcYyxf6O0CoA--~B/aD02MDA7dz0yNDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/business-wire.com/c4e480fc068297aa2a38c658567ba598"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/viridian-therapeutics-announces-participation-upcoming-120000202.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2439960290","title":"Qyuns Therapeutics AGM: Unanimous Resolutions Approval","url":"https://stock-news.laohu8.com/highlight/detail?id=2439960290","media":"TIPRANKS","top":-1,"share":"https://ttm.financial/m/news/2439960290?lang=en_us&edition=fundamental","pubTime":"2024-05-31 19:43","pubTimestamp":1717155839,"startTime":"0","endTime":"0","summary":"Qyuns Therapeutics Co., Ltd. Class H (HK:2509) has released an update. Qyuns Therapeutics Co., Ltd. conducted its Annual General Meeting (AGM) on M...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/qyuns-therapeutics-agm-unanimous-resolutions-approval?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/qyuns-therapeutics-agm-unanimous-resolutions-approval?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"gpt_icon":0}],"profile":{"websiteUrl":"http://lenz-tx.com","stockEarnings":[{"period":"1week","weight":-0.0261},{"period":"1month","weight":-0.0329},{"period":"3month","weight":-0.3557},{"period":"6month","weight":-0.0335},{"period":"1year","weight":-0.252},{"period":"ytd","weight":-0.1663}],"compareEarnings":[{"period":"1week","weight":-0.0039},{"period":"1month","weight":0.054},{"period":"3month","weight":0.0283},{"period":"6month","weight":0.1487},{"period":"1year","weight":0.2502},{"period":"ytd","weight":0.1095}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"TherapeuticsMD, Inc. operates as a pharmaceutical company in the United States. It has a license  agreement with Mayne Pharma to commercialize the IMVEXXY,BIJUVA, and ANNOVERA prescription prenatal vitamin products sold under the BocaGreenMD and vitaMedMD brands. The company sells its prescription pharmaceutical products and prenatal vitamin products to wholesale distributors and retail pharmacy distributors. TherapeuticsMD, Inc. was founded in 2008 and is headquartered in Boca Raton, Florida.","yearOnYearQuotes":[{"month":1,"riseRate":0.333333,"avgChangeRate":-0.187611},{"month":2,"riseRate":0.666667,"avgChangeRate":0.15153},{"month":3,"riseRate":0,"avgChangeRate":-0.19103},{"month":4,"riseRate":0.333333,"avgChangeRate":-0.06634},{"month":5,"riseRate":0,"avgChangeRate":-0.187229},{"month":6,"riseRate":0.5,"avgChangeRate":0.042853},{"month":7,"riseRate":0.333333,"avgChangeRate":-0.062127},{"month":8,"riseRate":0.333333,"avgChangeRate":-0.052314},{"month":9,"riseRate":0.333333,"avgChangeRate":-0.028796},{"month":10,"riseRate":0.666667,"avgChangeRate":-0.037137},{"month":11,"riseRate":0.333333,"avgChangeRate":-0.124883},{"month":12,"riseRate":0.666667,"avgChangeRate":0.157581}],"exchange":"NASDAQ","name":"Therapeutics","nameEN":"Therapeutics"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.22.5","shortVersion":"4.22.5","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Therapeutics(LENZ),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Therapeutics(LENZ) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Therapeutics,LENZ,Therapeutics股票,Therapeutics股票老虎,Therapeutics股票老虎国际,Therapeutics行情,Therapeutics股票行情,Therapeutics股价,Therapeutics股市,Therapeutics股票价格,Therapeutics股票交易,Therapeutics股票购买,Therapeutics股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Therapeutics(LENZ),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Therapeutics(LENZ) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}